Top

Published in:

01-01-2017 | Original Paper

The action and mechanism of myrislignan on A549 cells in vitro and in vivo

Authors: XinGang Lu, Liu Yang, JingXian Chen, JiAn Zhou, XiaoDan Tang, YingGang Zhu, HongFu Qiu, Jie Shen

Published in: Journal of Natural Medicines | Issue 1/2017

Abstract

Myrislignan is a natural compound with little pharmacological study. In our investigation, we investigated the effect of myrislignan in the induction of apoptosis in A549 cells in vitro and in vivo. Myrislignan inhibited the proliferation of A549 cells in a dose- and time-dependent manner assayed by MTT. In addition, Hoechst flow cytometry showed that myrislignan significantly induced apoptosis and cell cycle arrest in A549 cells. The apoptosis and anti-cell proliferation was mediated by the activation of mitogen-activated protein kinase and the inhibition of epidermal growth factor receptor signal pathway, change of mitochondrial membrane potential, the releasing of c-Myc, the downregulation of the level of the anti-apoptotic protein Bcl-2, and the upregulation of the level of the pro-apoptotic protein Bax. In conclusion, those results reveal a potential mechanism for the anti-cancer effect of myrislignan on human lung cancer, while suggesting that myrislignan may be a promising compound for the treatment of lung cancer.

Available only for authorised users

Wang Y, Sun Y (2015) Clinical experiences with molecular targeted therapy in lung cancer in China. Thorac Cancer 6(4):379–384CrossRefPubMedPubMedCentral

Johnson DH, Schiller JH, Bunn PA Jr (2014) Recent clinical advances in lung cancer management. J Clin Oncol 32(10):973–982CrossRefPubMed

DeSantis C, Naishadham D, Jemal A (2013) Cancer statistics for African Americans, 2013. CA Cancer J Clin 63(3):151–166CrossRefPubMed

Spira A, Halmos B, Powell CA (2015) Update in lung cancer 2014. Am J Respir Crit Care Med 192(3):283–294CrossRefPubMedPubMedCentral

Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA (2014) Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85(2):101–109CrossRefPubMedPubMedCentral

Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121(5):664–672CrossRefPubMed

Suda K, Sato K, Mizuuchi H, Kobayashi Y, Shimoji M, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T (2014) Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respir Investig 52(6):322–329CrossRefPubMed

Badr CE, Van Hoppe S, Dumbuya H, Tjon-Kon-Fat LA, Tannous BA (2013) Targeting cancer cells with the natural compound obtusaquinone. J Natl Cancer Inst 105(9):643–653CrossRefPubMedPubMedCentral

Yang XW, Huang X, Ahmat M (2008) New neolignan from seed of Myristica fragrans. Zhongguo Zhong Yao Za Zhi 33(4):397–402PubMed

10.

Li F, Yang XW (2008) Quantification of myrislignan in rat plasma by solid-phase extraction and reversed-phase high-performance liquid chromatography. Biomed Chromatogr 22(6):601–605CrossRefPubMed

11.

Du SS, Yang K, Wang CF, You CX, Geng ZF, Guo SS, Deng ZW, Liu ZL (2014) Chemical constituents and activities of the essential oil from Myristica fragrans against cigarette beetle Lasioderma serricorne. Chem Biodivers 11(9):1449–1456CrossRefPubMed

12.

Cao GY, Xu W, Yang XW, Gonzalez FJ, Li F (2015) New neolignans from the seeds of Myristica fragrans that inhibit nitric oxide production. Food Chem 173:231–237CrossRefPubMed

13.

Li F, Yang XW (2008) Biotransformation of myrislignan by rat liver microsomes in vitro. Phytochemistry 69(3):765–771CrossRefPubMed

14.

Jin H, Zhu ZG, Yu PJ, Wang GF, Zhang JY, Li JR, Ai RT, Li ZH, Tian YX, Zhang WX, Wu SG (2012) Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-kappaB signalling pathway activation. Phytother Res 26(9):1320–1326CrossRefPubMed

15.

Yang XW, Huang X, Ma L, Wu Q, Xu W (2010) The intestinal permeability of neolignans from the seeds of Myristica fragrans in the Caco-2 cell monolayer model. Planta Med 76(14):1587–1591CrossRefPubMed

16.

Wang Y, Liu JX, Zhang YB, Li F, Yang XW (2012) Determination and distribution study of myrislignan in rat tissues by RP-HPLC. Chromatographia 75:541–549CrossRef

17.

Chen Z, Huang X, Yang H, Ding W, Gao L, Ye Z, Zhang Y, Yu Y, Lou Y (2011) Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo. Chem Biol Interact 189(1–2):90–99CrossRefPubMed

18.

Estaquier J, Vallette F, Vayssiere JL, Mignotte B (2012) The mitochondrial pathways of apoptosis. Adv Exp Med Biol 942:157–183CrossRefPubMed

19.

Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, Sandomenico C, Giordano P, Normanno N, Perrone F, Rocco G, Di Maio M (2014) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 91(3):257–270CrossRefPubMed

20.

Chaveli-López B (2014) Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent 6(1):e81–e90CrossRefPubMedPubMedCentral

21.

Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, Guo J, Chen X, Wang Y (2011) Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 6(1):27CrossRefPubMedPubMedCentral

22.

Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A (2007) Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett 245(1–2):269–274CrossRefPubMed

23.

Griffin C, Karnik A, McNulty J, Pandey S (2011) Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts. Mol Cancer Ther 10(1):57–68CrossRefPubMed

24.

Kalemkerian GP (2014) Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 15(16):2385–2396CrossRefPubMed

25.

Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51(5):1417–1423CrossRefPubMed

26.

Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77(6):400–410CrossRefPubMed

27.

Uribe P, Gonzalez S (2011) Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 207(6):337–342CrossRefPubMed

28.

Bai Y, Yu W, Han N, Yang F, Sun Y, Zhang L, Zhao M, Huang L, Zhou A, Wang F, Li X (2013) Effects of semaphorin 3A on retinal pigment epithelial cell activity. Invest Ophthalmol Vis Sci 54(10):6628–6638CrossRefPubMed

29.

Kuroda S, Tam J, Roth JA, Sokolov K, Ramesh R (2014) EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomed 9:3825–3839

30.

Lee H, Lee H, Chin H, Kim K, Lee D (2014) ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget 5(13):5138–5152CrossRefPubMedPubMedCentral

31.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792CrossRefPubMed

32.

Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen AK (2016) Afatinib, an irreversible EGFR family inhibitor, shows activity toward pancreatic cancer cells, alone and in combination with radiotherapy, independent of KRAS status. Target Oncol 11(3):371–381CrossRefPubMed

33.

Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM (2015) Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin 36(5):614–626CrossRefPubMedPubMedCentral

34.

Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D’Alessio A, Menard S (2008) Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 112(1):25–33CrossRefPubMed

35.

Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26(22):3279–3290CrossRefPubMed

36.

Burova EB, Smirnova IS, Gonchar IV, Shatrova AN, Nikolsky NN (2011) Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNgamma-induced apoptosis. Cell Cycle 10(13):2197–2205CrossRefPubMed

37.

Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL (2012) Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep 39(7):7743–7753CrossRefPubMedPubMedCentral

38.

Zhang XJ, Zhang L, Liu YP, Xu HM, Sun P, Song JG, Luo YH (2013) Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway. Zhonghua Zhong Liu Za Zhi 35(3):181–186PubMed

39.

Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, Zhang G (2010) Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology 62(6):573–583CrossRefPubMedPubMedCentral

40.

Ashkenazi A, Salvesen G (2014) Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol 30:337–356CrossRefPubMed

41.

Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7(12). pii: a006080

42.

Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y (2008) Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272(1):61–69CrossRefPubMed

Title: The action and mechanism of myrislignan on A549 cells in vitro and in vivo
Authors: XinGang Lu
Liu Yang
JingXian Chen
JiAn Zhou
XiaoDan Tang
YingGang Zhu
HongFu Qiu
Jie Shen
Publication date: 01-01-2017
Publisher: Springer Japan
Published in: Journal of Natural Medicines / Issue 1/2017
Print ISSN: 1340-3443
Electronic ISSN: 1861-0293
DOI: https://doi.org/10.1007/s11418-016-1029-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The action and mechanism of myrislignan on A549 cells in vitro and in vivo

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness

Pteleifolols A–E, acetophenone di-C-glycosides and a benzopyran dimer from the leaves of Melicope pteleifolia

Hypouricemic effect of flaccidoside II in rodents

Carbazole alkaloids from Murraya koenigii trigger apoptosis and autophagic flux inhibition in human oral squamous cell carcinoma cells

Two new compounds from Trollius chinensis Bunge

Hypocholesterolemic effect of sericin-derived oligopeptides in high-cholesterol fed rats